Zusammenfassung auf Deutsch gibt es weiter unten. Ebenfalls Slides zum Anschauen.  
Synopsis of our Lumendi Ltd. event, including slides for your perusal.

Recently, a few people got together to learn more about the Endolumenal Surgical Platform (ESP) developed by Lumendi Inc.

In short, ESP is a medical device that dramatically increases current endoscopes’ capabilities. It enables the performance of many more procedures entirely via the lumen of the colon, which is minimally invasive compared to open or laparoscopic surgery.

For this event, we had three presenters:

Gerd Silberhumer, Surgical Oncologist at Universitätsklinik Wien (Vienna General Hospital) and member of the Lumendi Medical Advisory Board (medical matters)
Dr. Peter Johann, Chairman Lumendi Ltd (product pipeline, strategy and timetable)
Professor Urs E. Gattiker, PhD (moderator, cost-benefit data)

Of particular interest at this well-attended event was the Question & Answer session toward the end of the presentation. Discussions continued during the reception held immediately following.

We hope to have another of these events soon.

What do you like most about minimally-invasive medical technology?
Have a question? Just ask us below, and we will answer!

Zusammenfassung

Abo bestellen für den Lumendi Newsletter (1 bis 2 x im Monat) 

Diese Woche hatten wir die Ehre, einigen Interessierten (siehe Foto oben) unsere Endoluminale Chirurgische Plattform (ESP) vorstellen zu dürfen.

Die Vorteile der Technik sind auf der rechten Seite in der Grafik unten skizziert.

Es war ein heisser Tag in Zürich mit über 35 Grad Celsius. Trotzdem hatten sich viele Leute die Mühe gemacht, unseren Event zu besuchen. Das freute uns natürlich sehr.

Wir hatten 3 Referenten:

–  Gerd Silberhumer, Surgical Oncologist Universitätsklinik Wien Lumendi Medical Advisory Board  (medizinische Aspekte)
– Dr. Peter Johann, Chairman Lumendi Ltd. (Produkte Pipeline, Strategie und Zeitplan)
– Professor Urs E. Gattiker, Ph.D. (Moderator, Kosten-Nutzen, Daten)

Nach dem formalen Teil ging es dann zum Empfang mit Imbiss. Teilnehmer/Innen nutzten die Zeit auch zu angeregten Gesprächen.  Dabei ging es um das ESP wie auch andere interessante Dinge.

Wir hoffen, dass wir bald wieder einen solchen Event organisieren können.

Haben sie eine Frage an uns? Hinterlassen sie einen Kommentar und wir werden ihnen antworten.
Professor Urs E. Gattiker - DrKPI is corporate Europe's leading social media metrics expert (see his books). He continues to work with start-ups. Urs is CEO of CyTRAP Labs GmbH.

9 Thoughts on “Zurich Event”

  • Thanks for your comments, they are spot on with the vision of Lumendi to develop new approaches and devices enabling minimally invasive GI interventions.
    We will pursue our development plan as fast as reasonably possible to bring these devices through the approval process and to the patients to achieve all the benefits you described before.

    Peter Johann, Chairman Lumendi

    • Thanks for the update, Peter, looking forward to hearing more about this in the not too distant future.

      I am particularly interested in the user experience and how patients are included in the service design. You can tell because of my interest in co-production of health: http://blog.careum.ch/blog/koproduktion-2/

      Does that make any sense from your perspective, meaning from the private sector?
      Kind regards, Joerg

  • Dear Joerg,
    Highly interesting link you are providing!

    I definitely agree with you that patients should get involved in the different possibilities of treatment they could receive to appropriately address their health issues. Nevertheless there are still plenty of patients who accept doctors’ opinion as the “holy gral”.

    Our devices will enable and simplify currently challenging endoluminal procedures. Further they will push the limits further. As well, they will allow the treatment of certain diseases endoluminally, that have required classical surgical procedures so far.

    I am pretty sure patients are more likely to ask for minimal invasive procedures in the future. They will search the internet and make up their mind where they can get the best available treatment for their current problem and will no longer follow the “first advise” of their primary care taker.

    Nevertheless I still believe proper medical consenting and detailed discussion on treatment alternatives remain the key issues in best medical care.

    Kind regards

    Gerd Silberhumer, member of the medical advisory board

    • Dear Gerd,

      I fully agree with your statements and thanks for the feedback.

      In my humble opinion it is imperative to successfully link innovative treatment possibilities (like your advanced technology) with adequate health communication / shared-decision making. This helps us in coming up with the most patient-centred treatment option. In turn, the latter is then guided by patient education and self-management support, to further improve the outcomes of the treatment.

      Best wishes,

      Joerg

Leave a Reply

Your email address will not be published. Required fields are marked *